---
title: "Bluebird Bio (BLUE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BLUE.US.md"
symbol: "BLUE.US"
name: "Bluebird Bio"
industry: "Biotechnology"
datetime: "2026-05-20T09:37:07.517Z"
locales:
  - [en](https://longbridge.com/en/quote/BLUE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BLUE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BLUE.US.md)
---

# Bluebird Bio (BLUE.US)

## Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.64)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 349 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 127.51% |  |
| Net Profit YoY | 33.48% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 103946000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -546.54% | E |
| Profit Margin | -192.39% | E |
| Gross Margin | 68.39% | A |
| Revenue YoY | 127.51% | A |
| Net Profit YoY | 33.48% | B |
| Total Assets YoY | -53.13% | E |
| Net Assets YoY | -144.16% | E |
| Cash Flow Margin | -51.98% | E |
| OCF YoY | 127.51% | A |
| Turnover | 0.22 | D |
| Gearing Ratio | 119.55% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Bluebird Bio",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "127.51%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "33.48%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "103946000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-546.54%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-192.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "68.39%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "127.51%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "33.48%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-53.13%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-144.16%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-51.98%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "127.51%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "119.55%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.24 | 116/386 | - | - | - |
| PB | -0.84 | 535/386 | - | - | - |
| PS (TTM) | 0.47 | 21/386 | 0.47 | 0.47 | 0.47 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.97 |
| Highest Target | 8.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BLUE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BLUE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BLUE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BLUE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**